Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially ...

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing ...

Northwestern Medicine investigators have uncovered a missing link behind the harmful effects of autoantibodies linked to blood clots, pregnancy complications and other inflammatory conditions, ...

The implementation of COVID-19 vaccines has proven highly effective against the development of severe disease, hospitalisation, and death. There is a good correlation between antibody binding and ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact cause is unknown. Possible C3G causes include genetic mutations, autoantibodies, and certain autoimmune conditions.

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

FDA and EMA accepts Regeneron's submissions for review of cemdisiran: New York Wednesday, June 24, 2026, 15:00 Hrs [IST] Regeneron Pharmaceuticals, Inc., announced that both the U ...

Regeneron Pharmaceuticals has announced that both the US FDA and the European Medicines Agency (EMA) have accepted the ...

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile. Freimer was an author on 5 abstracts presented at the ...

Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...